AGC Biologics vs Charles River Laboratories: CDMO Comparison
How does AGC Biologics compare to Charles River Laboratories for AAV manufacturing?
Side-by-side comparison of AGC Biologics and Charles River Laboratories on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Charles River Laboratories has more FDA inspections on record (8 vs 2) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- AGC Biologics has materially broader EMA GMP coverage (23 active certificates vs 9) — stronger EU footprint.
- Charles River Laboratories maintains 2 MHRA / UK GMP certificates; AGC Biologics does not.
- Composite Signal Score: Charles River Laboratories 92/100 vs AGC Biologics 81/100 — a 11-point gap reflecting the combined quality, capacity and financial signal.
On a 13-modality CDMO landscape, both AGC Biologics and Charles River Laboratories qualify as AAV manufacturers; Charles River Laboratories carries the higher composite Signal Score for AAV programs in this comparison.
What to evaluate for AAV programs
Both AGC Biologics and Charles River Laboratories qualify as AAV CDMOs. When choosing between them for AAV programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Platform & scale
Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.
Capsid quality
Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.
Regulatory readiness
For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & timelines
AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.
Frequently asked: AGC Biologics vs Charles River Laboratories
How does AGC Biologics compare to Charles River Laboratories for AAV manufacturing?
On CDMO Signal's composite Signal Score, AGC Biologics is 81/100 and Charles River Laboratories is 92/100; AGC Biologics has 2 FDA inspections on record vs 8 for Charles River Laboratories; European coverage is 23 active EMA+MHRA certificates for AGC Biologics vs 11 for Charles River Laboratories. Both are tracked in the CDMO Signal directory as AAV CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, AGC Biologics or Charles River Laboratories?
Both AGC Biologics and Charles River Laboratories maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. AGC Biologics has 2 FDA inspections on record; Charles River Laboratories has 8.
How do AGC Biologics and Charles River Laboratories compare on European GMP coverage?
AGC Biologics holds 23 active EMA GMP certificates and 0 MHRA / UK certificates. Charles River Laboratories holds 9 active EMA GMP certificates and 2 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — AGC Biologics or Charles River Laboratories?
AGC Biologics is matched to 2 ClinicalTrials.gov records as a manufacturing partner; Charles River Laboratories is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for AAV manufacturing — AGC Biologics or Charles River Laboratories?
Both AGC Biologics and Charles River Laboratories are tagged as AAV CDMOs in our directory, so both are credible options for AAV programs. The most important differentiator for AAV selection is typically platform & scale: Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →